– 4C Medical is developing the first MR treatment that preserves the native mitral valve and left ventricle using a supra-annular, atrial-only fixation technology. The novel design eliminates issues associated with current transcatheter mitral valve replacement (TMVR) technologies – which rely on placement and fixation in the native mitral annulus and left ventricle – such as obstruction of the left ventricular outflow tract, impaired function of the left ventricle and device embolization.
Philippe Ge’ne’reux, MD presented “A Novel Transcatheter MR Technology System (4C valve)” in which he explained how the 4C valve may extend TMVR therapy to patients who would be ineligible for alternative TMVR procedures. Dr. Ge’ne’reux is Co-Director of the Structural Heart Program at the Gagnon Cardiovascular Institute of Morristown Medical Center (Morristown, NJ) and a practicing Interventional Cardiologist at Hopital du Sacre’-Coeur de Montre’al (Montreal, Canada).
“Delivered transseptally, the 4C valve will provide a treatment option for a broad MR patient population – including patients that can be treated by other TMVR devices, patients that cannot be treated by other TMVR devices, and even patients with previously failed mitral repair,” said Dr. Ge’ne’reux. “Because the device is placed and anchored entirely in the left atrium, it does not rely on or interact with the dynamic and irregular anatomy of the mitral annulus and left ventricle. 4C Medical’s technology will answer a real unmet clinical need.”
“We are honored that the ICI organizers invited 4C Medical to present our novel TMVR technology,” said Robert Thatcher, CEO of 4C Medical. “We will carry this momentum forward as we complete bench and pre-clinical testing in preparation for the early feasibility study. Because fewer patients will be excluded from our study as compared to other TMVR device trials, we anticipate quicker enrollment.”
About 4C Medical Technologies, Inc.4C Medical is a medical device company developing minimally invasive technologies for structural heart disease, focusing initially on mitral regurgitation (MR) therapy and, in the future, on tricuspid regurgitation therapy. The company’s transcatheter mitral valve device is the first MR treatment with supra-annular positioning and atrial-only fixation. It preserves the native mitral valve and left ventricle – eliminating known issues associated with other transcatheter mitral valve replacement (TMVR) technologies which rely on placement and fixation in the native mitral annulus and left ventricle – and will expand the patient population eligible for TMVR therapy.
Media ContactsRobert ThatcherChief Executive Officer(612) 600-8951[email protected]
Jim FlahertyChief Financial Officer(612) 599-0650[email protected]
Logo – http://mma.prnewswire.com/media/521129/4C_Medical_Technologies_Inc___Logo.jpg
(Immediapress – Adnkronos
Immediapress e’ un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. Padovanews non e’ responsabile per i contenuti dei comunicati trasmessi.)